HiSiaddi is an innovative foreign trade service provider driven by dual pillars of technology transformation and foreign trade services, operating under the “1+2+3+4=1” integrated service framework, with direct access to original manufacturer supplies of Clostridium butyricum and Bacillus coagulans.
As a technology-focused foreign trade enterprise, HiSiaddi has completed multiple on-site audits of Clostridium butyricum and Bacillus coagulans production manufacturers through technology conversion collaborations, accumulating objective, in-depth insights into each brand’s offerings. We regularly provide clients with cross-brand manufacturer analysis for Clostridium butyricum and Bacillus coagulans to facilitate optimal supplier matching. Below is a supplier matching recommendation case.
Contact HiSiaddi customer service for additional cross-brand model comparison analysis.
The client is NutraLife, a mid-to-high-end dietary supplement brand based in Germany specializing in adult intestinal health probiotics and immune support complex formulations. Its products are distributed through premium German pharmacies, organic supermarkets and online wellness platforms, fully compliant with German DIN standards, EU Regulation EC 1907/2006, non-GMO requirements, gluten-free specifications and ISO 22000 certification. End-product retail prices range from EUR 50 to 150, positioning the brand as a premium supplier of high-purity, high-viability formulations with robust regulatory compliance documentation.
In April 2026, the client planned to source compound Clostridium butyricum + Bacillus coagulans raw materials for its new balanced intestinal probiotic capsule line. Core client pain points included limited knowledge of China’s probiotic brand landscape, strain specifications, mainstream product models and technical capabilities. Four previously contacted manufacturers exclusively promoted their own products while evading cross-brand comparative data, leaving the client concerned about substandard viability, regulatory non-compliance and underperforming end products that would delay new product launches. The client urgently commissioned HiSiaddi to conduct objective cross-brand analysis of five leading manufacturers, compare core product models, and recommend two mid-to-high-end manufacturers plus three matching product models balancing quality, regulatory compliance and cost-effectiveness.
Based on six core evaluation dimensions—strain patent ownership, viability performance, technical barriers, regulatory compliance credentials, market reputation and suitability for high-end formulation production—HiSiaddi selected five top-tier mid-to-high-end domestic manufacturers (Qingdao Donghai Pharmaceutical, Henan Jinbaihe Biotechnology, Heshivo Biotechnology, Guangdong Dazenong Biotechnology, Shandong Baolai Lailai Bioengineering) for blind testing and unbiased cross-brand comparison, eliminating brand bias to transparently present each manufacturer’s strengths and limitations.
Brand Positioning: China’s sole industrialized production base for pharmaceutical-grade microecological strains, a national high-tech enterprise specializing in R&D and manufacturing of Clostridium butyricum (Clostridium tyrobutyricum) and Bacillus coagulans, with core strengths in ultra-high stability, safety and clinically validated strains.
Core Strains & Product Models
· Bacillus coagulans TBC169 (Pharmaceutical-Grade): China’s first Bacillus coagulans strain approved for pharmaceutical drug licensing, minimum viable count ≥5×10⁹ CFU/g, spore rate ≥98%, 24-month ambient stability, exceptional gastric acid and storage resistance supported by comprehensive clinical validation.
· Clostridium butyricum CGMCC0313.1 (Raw Material Grade for Aitaining): Pharmaceutical-grade strain with minimum viable count ≥3×10⁹ CFU/g, ultra-low impurity content, ideal for premium formulations.
Strengths: Exclusive patented strains, pharmaceutical-grade quality control, exceptional stability, complete regulatory compliance filings (FDA registration, EU Novel Food certification), suitable for premium dietary supplements and pharmaceutical-grade raw materials.
Limitations: Premium pricing, limited Clostridium butyricum product range, reduced flexibility for small-batch customization.
Brand Positioning: National “Specialized, Refined, Unique, Innovative” Little Giant enterprise, formulator of the national Clostridium butyricum industry standard, China’s largest high-yield Clostridium butyricum manufacturer with mature, stable mass production technology.
Core Strains & Product Models
· 10 Billion CFU/g Clostridium Butyricum (Yiqikang Model): Industry benchmark product with minimum viable count ≥1×10¹⁰ CFU/g, spore rate ≥95%, short-term heat resistance up to 60°C, compatible with feed and food-grade raw material applications.
· Compound Clostridium Butyricum (Antibiotic Replacement Grade): Blended with lactic acid bacteria and bacilli, minimum viable count ≥5×10⁹ CFU/g, outstanding cost-performance ratio.
Strengths: Industry-leading Clostridium butyricum technology, large production capacity, consistent lead times, moderate pricing, extensive product model portfolio, full ISO/GMP certification, ideal for mid-to-high-end food and dietary supplement applications.
Limitations: Bacillus coagulans production is not its core competitive advantage, limited product range and slightly lower viability compared to Donghai Pharmaceutical.
Brand Positioning: National high-tech and Specialized, Refined, Unique, Innovative enterprise specializing in stabilized probiotics and microcapsule coating technology, with joint R&D partnerships with China Agricultural University and the Institute of Microbiology, Chinese Academy of Sciences, focusing on ultra-stress-resistant, formulation-compatible strains.
Core Strains & Product Models
· Channeng (Microencapsulated Clostridium Butyricum): Minimum viable count ≥5×10⁹ CFU/g, ≥90% viability after 6 hours in pH 2.0 gastric fluid, targeted intestinal release optimized for capsule formulations.
· High-Viability Bacillus Coagulans BC-30: Minimum viable count ≥8×10⁹ CFU/g, spore rate ≥96%, exceptional stress resistance.
Strengths: Industry-leading microcapsule coating technology, highly stress-resistant strains, excellent formulation compatibility, robust in-house R&D capabilities, full regulatory compliance, ideal for premium capsules and tablets.
Limitations: Moderately high pricing, smaller production capacity than Jinbaihe, slightly extended lead times.
Brand Positioning: National high-tech enterprise specializing in premium bacilli and lactic acid bacteria, with joint R&D partnerships with the Chinese Academy of Sciences and Jiangnan University, focusing on ultra-high-purity, high-viability strains and flexible custom compounding services.
Core Strains & Product Models
· DZN-10 Clostridium Butyricum: Minimum viable count ≥6×10⁹ CFU/g, spore rate ≥95%, allergen-free formulation.
· DZN-20 Bacillus Coagulans: Minimum viable count ≥7×10⁹ CFU/g, exceptional long-term stability.
Strengths: Highly flexible custom blending capabilities, ultra-high strain purity, complete regulatory compliance, suitable for small-to-medium batch premium customization.
Limitations: Lower brand market recognition, limited production capacity, premium pricing.
Brand Positioning: China’s listed manufacturer of microecological formulations, full-spectrum probiotic supplier with extensive production capacity and distribution networks, offering cost-effective comprehensive product portfolios and nationwide service coverage.
Core Strains & Product Models
· BL-100 Clostridium Butyricum: Minimum viable count ≥4×10⁹ CFU/g, low-cost formulation optimized for feed-grade applications.
· BL-200 Bacillus Coagulans: Minimum viable count ≥5×10⁹ CFU/g, superior cost-performance ratio.
Strengths: Lowest pricing, largest production capacity, fastest lead times, full product category coverage, ideal for mid-to-entry-level market applications.
Limitations: Subpar strain viability and stability, no proprietary patented strains, limited high-end regulatory compliance documentation, unsuitable for premium dietary supplement production.
Aligned with the client’s requirements for German premium dietary supplements in capsule format, demanding high viability, exceptional stability, full regulatory compliance and medium monthly order volumes (1 ton/month), HiSiaddi eliminated Baolai Lailai (insufficient viability and regulatory credentials) and Dazenong (limited production capacity), ultimately recommending two mid-to-high-end manufacturers alongside three matching product models balancing quality, compliance and cost-effectiveness:
Recommended Model: Bacillus Coagulans TBC169 (Pharmaceutical Licensed Grade) Rationale for Recommendation:
1. Exclusive proprietary strain: China’s sole pharmaceutical-grade Bacillus coagulans with comprehensive clinical validation, widely recognized within the German market.
2. Industry-leading viability and stability: Minimum viable count ≥5×10⁹ CFU/g, spore rate ≥98%, consistent stability over 24 months ambient storage, meeting Germany’s extended shelf-life requirements.
3. Complete regulatory compliance: FDA registration, EU Novel Food certification, non-GMO declarations supporting direct German customs clearance and product registration.
4. Capsule-compatible powder properties: Excellent flowability, zero residual auxiliary excipients, optimized for capsule filling processes.
Recommended Model 1: Channeng Microencapsulated Clostridium Butyricum Rationale for Recommendation: ≥90% viability post gastric acid exposure with targeted intestinal release, perfectly matching capsule formulation demands; minimum viable count ≥5×10⁹ CFU/g with exceptional stability, fully aligned with German premium product standards.
Recommended Model 2: High-Viability Bacillus Coagulans BC-30 Rationale for Recommendation: Minimum viable count ≥8×10⁹ CFU/g, spore rate ≥96%, robust stress resistance, complementary performance to Donghai’s TBC169 for flexible blending; moderately priced with complete regulatory compliance filings.
Henan Jinbaihe Biotechnology (Backup Clostridium Butyricum Supplier): Yiqikang 10 Billion CFU/g Clostridium Butyricum, ultra-high viability, moderate pricing and large production capacity as a cost-effective backup alternative to Heshivo.
The client received samples of the three recommended models and submitted them to Eurofins’ German third-party laboratory for independent testing:
· Donghai TBC169: 5.8×10⁹ CFU/g viable count, 98.2% spore rate, verified 24-month stability, fully compliant with specifications.
· Heshivo Channeng: 5.3×10⁹ CFU/g viable count, 91.8% post-gastric-acid viability, meets all requirements.
· Heshivo BC-30: 8.5×10⁹ CFU/g viable count, 96.7% spore rate, fully compliant.
HiSiaddi coordinated full sets of English regulatory filings (strain patents, FDA registration, EU Novel Food certification, non-GMO declarations, COA, GMP certificates) for client review by the German legal team; all documentation achieved 100% compliance with EU and German regulatory standards for direct product registration.
The client fully approved HiSiaddi’s unbiased cross-brand evaluation and matching recommendations, issuing formal purchase orders:
· Bacillus coagulans: Qingdao Donghai TBC169 (500kg monthly volume)
· Clostridium butyricum: Heshivo Channeng (500kg monthly volume)
· Backup raw material: Jinbaihe Yiqikang (300kg monthly contingency stock)
1.
Client Feedback “HiSiaddi is our most reliable impartial supplier selection consultant for China market entry. China’s fragmented probiotic brand landscape creates opaque information asymmetry, with every manufacturer exclusively promoting their own products without transparent cross-brand comparisons. HiSiaddi maintains neutrality, completing cross-brand evaluations of five manufacturers to transparently present respective strengths and limitations, and precisely match our German premium formulation requirements. The two manufacturers and three product models they recommended deliver fully compliant viability, stability and regulatory credentials, helping us avoid costly supplier selection pitfalls while saving significant time and expenses—an indispensable long-term strategic partner.”
2.
3.
Core Case Value Overseas mid-to-high-end clients sourcing Clostridium butyricum and Bacillus coagulans primarily face information asymmetry risks, self-biased manufacturer sales messaging and lack of objective cross-brand benchmarking, frequently leading to substandard quality, regulatory violations and failed end-product launches due to poor supplier selection.
4.
HiSiaddi’s core value proposition lies in unbiased third-party evaluation + specialized technical screening + demand-aligned precise matching:
· Fully independent cross-brand benchmarking free from manufacturer affiliations, transparently disclosing all brand strengths and weaknesses.
· Targeted supplier screening aligned with core client requirements for premium formulations, ultra-high viability, long-term stability and full regulatory compliance.
· End-to-end support including sample testing, regulatory documentation auditing and technical liaison to mitigate client supplier selection risks.
· Balanced quality, regulatory adherence and cost-effectiveness to satisfy premium market standards while controlling procurement costs, accelerating client new product commercialization.
Contact HiSiaddi customer service for additional cross-brand model comparison analysis.
+86-13120989737 
info@hisiaddi.com 
English
